home

Domestic Pharma Growth Improves for the month of May

Sequentially, the domestic pharma industry staged an improvement for the month of May. According to data compiled by PharmaTrac, at 9.9%, the growth is best in the year 2013. 

There was an improvement of growth in case of the anti-infectives segment, being the largest category in the Indian pharmaceutical market constituting nearly 18% of the industry revenues. From therapy perspective 9 therapies have outgrown the IPM growth. Respiratory market grew at 10.4%, anti-diabetic market increased 12.5% and cardiac at 12.9% in chronic business. Amongst top 10 therapies, Neuro/CNS market grew the highest at 13.2%. 

Amongst the top 10 companies, Zydus group of companies grew at 24.3%, 
Sun PharmaBSE 0.67 % at 21.2%, & RanbaxyBSE 1.48 %registered growth of 20.2%.